Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are
immunotherapies that target various B cell–related proteins. Most of these treatments have …

This manuscript presents practical recommendations for managing acute attacks and
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …

Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis
(MS)(in particular the progressive forms) still represents an important unmet medical need …

Background and Objectives To determine the frequency of hypogammaglobulinemia and
infections in patients with multiple sclerosis (PwMS) receiving rituximab (RTX). Methods This …

Background and Objectives B cell–depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …

Background and Objectives To investigate the frequency and predictors of
hypogammaglobulinemia during long-term rituximab (RTX) treatment in patients with …

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing-remitting
neuroinflammatory disorder of the central nervous system (CNS) usually associated with …

Hypogammaglobulinemia is characterized by reduced serum immunoglobulin levels.
Secondary hypogammaglobulinemia is of considerable interest to the practicing physician …

Background and Objectives The use of highly effective multiple sclerosis (MS) disease-
modifying therapies (DMTs) is rapidly increasing. Yet, little is known about their real-world …